These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 20049443)

  • 1. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment.
    Bello CL; Garrett M; Sherman L; Smeraglia J; Ryan B; Toh M
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):699-707. PubMed ID: 20049443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function.
    Khosravan R; Toh M; Garrett M; La Fargue J; Ni G; Marbury TC; Swan SK; Lunde NM; Bello CL
    J Clin Pharmacol; 2010 Apr; 50(4):472-81. PubMed ID: 19779038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
    Houk BE; Bello CL; Poland B; Rosen LS; Demetri GD; Motzer RJ
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):357-71. PubMed ID: 19967539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
    Britten CD; Kabbinavar F; Hecht JR; Bello CL; Li J; Baum C; Slamon D
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):515-24. PubMed ID: 17505827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients.
    Houk BE; Bello CL; Kang D; Amantea M
    Clin Cancer Res; 2009 Apr; 15(7):2497-506. PubMed ID: 19258444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
    Kloth JS; Binkhorst L; de Wit AS; de Bruijn P; Hamberg P; Lam MH; Burger H; Chaves I; Wiemer EA; van der Horst GT; Mathijssen RH
    Clin Pharmacokinet; 2015 Aug; 54(8):851-8. PubMed ID: 25647628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
    Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function.
    Slingerland M; Hess D; Clive S; Sharma S; Sandstrom P; Loman N; Porro MG; Mu S; Waldron E; Valera SZ; Gelderblom H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1089-98. PubMed ID: 25253045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
    Simonson SG; Martin PD; Mitchell P; Schneck DW; Lasseter KC; Warwick MJ
    Eur J Clin Pharmacol; 2003 Feb; 58(10):669-75. PubMed ID: 12610743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
    Horak J; White J; Harris AL; Verrill M; Carmichael J; Holt A; Cantarini M; Macpherson M; Swaisland A; Swaisland H; Twelves C
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1485-95. PubMed ID: 21487718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asenapine pharmacokinetics in hepatic and renal impairment.
    Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
    Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and pharmacokinetic profile of a sunitinib powder formulation in pediatric patients with refractory solid tumors: a Children's Oncology Group study.
    DuBois SG; Shusterman S; Reid JM; Ingle AM; Ahern CH; Baruchel S; Glade-Bender J; Ivy P; Adamson PC; Blaney SM
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1021-7. PubMed ID: 22179104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.
    Yu H; Steeghs N; Kloth JS; de Wit D; van Hasselt JG; van Erp NP; Beijnen JH; Schellens JH; Mathijssen RH; Huitema AD
    Br J Clin Pharmacol; 2015 May; 79(5):809-19. PubMed ID: 25393890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study.
    Peveling-Oberhag J; Zeuzem S; Yong WP; Kunz T; Paquet T; Bouillaud E; Urva S; Anak O; Sellami D; Kobalava Z
    Clin Ther; 2013 Mar; 35(3):215-25. PubMed ID: 23453404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species.
    Haznedar JO; Patyna S; Bello CL; Peng GW; Speed W; Yu X; Zhang Q; Sukbuntherng J; Sweeny DJ; Antonian L; Wu EY
    Cancer Chemother Pharmacol; 2009 Sep; 64(4):691-706. PubMed ID: 19169880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment.
    Kurata A; Yoshida T; Inoue M; Ishizuka T; Nakatsu T; Shimizu T; Kato M; Nishikawa Y; Ishizuka H
    Adv Ther; 2020 Jan; 37(1):253-264. PubMed ID: 31705436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of pharmacokinetics and safety of ponatinib in subjects with chronic hepatic impairment and matched healthy subjects.
    Narasimhan NI; Dorer DJ; Davis J; Turner CD; Marbury TC; Sonnichsen D
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):341-8. PubMed ID: 24934866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label, Single-dose Studies of the Pharmacokinetics of Edaravone in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects with Normal Hepatic Functioning.
    Nakamaru Y; Kakubari M; Yoshida K; Akimoto M; Todorovic V; Greis T; Kondo K
    Clin Ther; 2020 Aug; 42(8):1467-1482.e4. PubMed ID: 32800532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.